Literature DB >> 24642648

Vaginal lactoferrin administration before genetic amniocentesis decreases amniotic interleukin-6 levels.

Fortunato Vesce1, Emilio Giugliano, Stefania Bignardi, Elisa Cagnazzo, Cecilia Colamussi, Roberto Marci, Nicoletta Valente, Silvia Seraceni, Martina Maritati, Carlo Contini.   

Abstract

AIM: To verify the eventual efficacy of lactoferrin (LF), an iron-binding glycoprotein, to decrease the amniotic concentration of interleukin-6 (IL-6).
METHODS: We prospectively enrolled 60 Caucasian patients at the 16th week of their singleton physiological gestation. A vaginal compound containing 300 mg of LF was administered randomly 4 or 12 h prior to amniocentesis, as to obtain 3 groups: A, 20 untreated patients; B, 20 treated 4 h before amniocentesis; C, 20 treated 12 h before amniocentesis.
RESULTS: A normal karyotype was registered in all cases. The comparison of the distribution of IL-6 among the 3 groups showed a highly significant difference (p = 0.001). The difference between mean values of group B and both groups C and A was shown to be highly significant (p = 0.006 and p = 0.03, respectively). In contrast, there was no significant difference between mean values of groups A and C.
CONCLUSION: Vaginal LF administration decreases amniotic IL-6 concentration. We therefore suggest that the glycoprotein may exert a protective role against ominous pregnancy complications linked to an increased level of the cytokine, such as abortion secondary to amniocentesis.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24642648     DOI: 10.1159/000358877

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  8 in total

1.  Vaginal Lactoferrin Modulates PGE2, MMP-9, MMP-2, and TIMP-1 Amniotic Fluid Concentrations.

Authors:  Alessandro Trentini; Martina Maritati; Carlo Cervellati; Maria C Manfrinato; Arianna Gonelli; Carlo A Volta; Fortunato Vesce; Pantaleo Greco; Franco Dallocchio; Tiziana Bellini; Carlo Contini
Journal:  Mediators Inflamm       Date:  2016-10-31       Impact factor: 4.711

2.  Lactoferrin Enhanced Apoptosis and Protected Against Thioacetamide-Induced Liver Fibrosis in Rats.

Authors:  Alyaa Hessin; Rehab Hegazy; Azza Hassan; Nemat Yassin; Sanaa Kenawy
Journal:  Open Access Maced J Med Sci       Date:  2015-03-31

3.  Influence of vaginal lactoferrin administration on amniotic fluid cytokines and its role against inflammatory complications of pregnancy.

Authors:  Martina Maritati; Manola Comar; Nunzia Zanotta; Silva Seraceni; Alessandro Trentini; Fabrizio Corazza; Fortunato Vesce; Carlo Contini
Journal:  J Inflamm (Lond)       Date:  2017-02-15       Impact factor: 4.981

4.  Wearable Devices and Intelligent Application in Women's Postpartum Repair for Smart Healthcare.

Authors:  Jing Wang; Danfeng Wang
Journal:  J Healthc Eng       Date:  2022-01-07       Impact factor: 2.682

Review 5.  The Inflammatory Cytokine Imbalance for Miscarriage, Pregnancy Loss and COVID-19 Pneumonia.

Authors:  Fortunato Vesce; Chiara Battisti; Michele Crudo
Journal:  Front Immunol       Date:  2022-03-11       Impact factor: 7.561

Review 6.  The Immunological Role of the Placenta in SARS-CoV-2 Infection-Viral Transmission, Immune Regulation, and Lactoferrin Activity.

Authors:  Iwona Bukowska-Ośko; Marta Popiel; Paweł Kowalczyk
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

7.  Renoprotective Effect of Lactoferrin against Chromium-Induced Acute Kidney Injury in Rats: Involvement of IL-18 and IGF-1 Inhibition.

Authors:  Rehab Hegazy; Abeer Salama; Dina Mansour; Azza Hassan
Journal:  PLoS One       Date:  2016-03-18       Impact factor: 3.240

Review 8.  Antimicrobial and Prebiotic Activity of Lactoferrin in the Female Reproductive Tract: A Comprehensive Review.

Authors:  Jolanta Artym; Michał Zimecki
Journal:  Biomedicines       Date:  2021-12-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.